Induction of angiogenesis by normal and malignant plasma cells

Blood

Volumn 114, Issue 1, 2009, Pages 128-143

  Hose, Dirk ^a,b   Moreaux, Jérôme ^c,d   Meissner, Tobias ^a   Seckinger, Anja ^a   Goldschmidt, Hartmut ^a,b   Benner, Axel ^e   Mahtouk, Karène ^c,d   Hillengass, Jens ^a,e   Rème, Thierry ^c,d   De Vos, John ^c,d   Hundemer, Michael ^a   Condomines, Maud ^c,d   Bertsch, Uta ^a   Rossi, Jean François ^c,d   Jauch, Anna ^a   Klein, Bernard ^c,d   Möhler, Thomas ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Nationales Centrum fur Tumorerkrankungen   (Germany)

^c HÔPITAL SAINT ELOI   (France)

^d INSERM   (France)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 15; MELPHALAN; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN 1; SYNDECAN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN A; ANGIOGENIC PROTEIN; ANGIOSTATIC PROTEIN;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEMORY CELL; MICROCIRCULATION; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PURIFICATION; SUPERNATANT; B LYMPHOCYTE; BIOLOGICAL MODEL; BONE MARROW; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENIC PROTEINS; ANGIOSTATIC PROTEINS; B-LYMPHOCYTES; BONE MARROW; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS;

EID: 67651037336     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184226     Document Type: Article

References (52)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl J Med. 2004;351:1860-1873.
2. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503-508. (Pubitemid 24230014)
3. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102:3340-3348. (Pubitemid 37314776)
4. Nosas-Garcia S, Moehler T, Wasser K, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging. 2005;22:154-162. (Pubitemid 40885141)
5. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol. 2002;119:665-671. (Pubitemid 35366206)
6. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66:83-88. (Pubitemid 32154100)
7. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res. 2007;13:475-481. (Pubitemid 46225352)
8. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111-3116. (Pubitemid 30637735)
9. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79:574-577. (Pubitemid 30797624)
10. Kumar S, Lacy MQ, Dispenzieri A, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004;34:485-490. (Pubitemid 39264037)
11. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 2001;7: 2675-2681. (Pubitemid 32911371)
12. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88: 3998-4004. (Pubitemid 26383124)
13. Seidel C, Borset M, Turesson I, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma: the Nordic Myeloma Study Group. Blood. 1998;91:806-812.
14. Seidel C, Lenhoff S, Brabrand S, et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol. 2002;119:672-676. (Pubitemid 35366207)
15. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128: 210-217.
16. Seidel C, Borset M, Hjertner O, et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood. 2000;96:3139-3146. (Pubitemid 30815224)
17. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
18. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol. 2003;45:227-244.
19. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
20. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
21. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
22. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
23. Goldschmidt H, Sonneveld P, Cremer FW, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003;82:654-659. (Pubitemid 37407500)
24. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633-2638.
25. Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007;109:4914-4923. (Pubitemid 46827789)
26. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106:1021-1030. (Pubitemid 41076449)
27. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654-3663. (Pubitemid 24175556)
28. Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000;14:188-197. (Pubitemid 30068391)
29. Rebouissou C, Wijdenes J, Autissier P, et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998; 91:4727-4737. (Pubitemid 28270323)
30. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44:194-203. (Pubitemid 41306648)
31. Hose D, Reme T, Meissner T, et al. Inhibition of Aurora-kinases for tailored risk adapted treatment of multiple myeloma. Blood. 2009;113:4331-4340.
32. Mahtouk K, Hose D, Reme T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma: amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24:3512-3524. (Pubitemid 40756252)
33. Hillengass J, Zechmann CM, Nadler A, et al. Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. Int J Cancer. 2008;122: 2871-2875. (Pubitemid 351631392)
34. Wu Z, Irizarry RA, Gentleman RC, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004;99:909-917. (Pubitemid 39665934)
35. Warren P, Taylor D, Martini PGV, Jackson J, Bienkowska J. PANP-a new method of gene detection on oligonucleotide expression arrays. Bioinformatics Bioengineering, 2007. BIBE 2007. Proceedings of the 7th IEEE International Conference. October 14-17, 2007;108:115.
36. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:article3.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
38. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20:93-99.
39. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
40. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
41. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104:1159-1165. (Pubitemid 39038038)
42. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol. 2001;28:543-550. (Pubitemid 33134413)
43. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-3495. (Pubitemid 46572539)
44. Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581-1590.
45. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073. (Pubitemid 29200799)
46. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88:176-185. (Pubitemid 37101495)
47. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210-2216. (Pubitemid 34753592)
48. Niemoller K, Jakob C, Heider U, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol. 2003;129:234-238. (Pubitemid 36713799)
49. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999;104:131-137. (Pubitemid 29037031)
50. Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone Marrow Pathology. Oxford, United Kingdom: Blackwell Science; 2008:31-32.
51. Hayes AJ, Huang WQ, Mallah J, et al. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res. 1999;58:224-237. (Pubitemid 29531872)
52. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106-113. (Pubitemid 37021949)